Barge Joseph La Sells 5,500 Shares of Spark Therapeutics, Inc. (ONCE) Stock

Spark Therapeutics, Inc. (NASDAQ:ONCE) insider Barge Joseph La sold 5,500 shares of the business’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $71.44, for a total value of $392,920.00. Following the completion of the sale, the insider now owns 8,146 shares in the company, valued at $581,950.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Barge Joseph La also recently made the following trade(s):

  • On Thursday, November 9th, Barge Joseph La sold 3,309 shares of Spark Therapeutics stock. The shares were sold at an average price of $71.31, for a total value of $235,964.79.
  • On Tuesday, September 5th, Barge Joseph La sold 5,500 shares of Spark Therapeutics stock. The shares were sold at an average price of $81.00, for a total value of $445,500.00.

Spark Therapeutics, Inc. (NASDAQ ONCE) opened at $68.25 on Wednesday. Spark Therapeutics, Inc. has a 52-week low of $47.03 and a 52-week high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.11). Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The firm had revenue of $1.90 million during the quarter, compared to analysts’ expectations of $1.40 million. During the same quarter in the previous year, the company posted ($1.07) earnings per share. Spark Therapeutics’s revenue for the quarter was up 45.8% compared to the same quarter last year. research analysts anticipate that Spark Therapeutics, Inc. will post -7.62 EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was originally posted by Markets Daily and is the property of of Markets Daily. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.themarketsdaily.com/2017/11/15/barge-joseph-la-sells-5500-shares-of-spark-therapeutics-inc-once-stock.html.

Several institutional investors and hedge funds have recently bought and sold shares of ONCE. Ameritas Investment Partners Inc. boosted its holdings in shares of Spark Therapeutics by 23.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 389 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Spark Therapeutics in the 2nd quarter worth about $143,000. BNP Paribas Arbitrage SA boosted its holdings in shares of Spark Therapeutics by 530.1% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock worth $174,000 after purchasing an additional 2,449 shares in the last quarter. Pacad Investment Ltd. boosted its holdings in shares of Spark Therapeutics by 75.0% in the 2nd quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 1,500 shares in the last quarter. Finally, Teacher Retirement System of Texas purchased a new position in shares of Spark Therapeutics in the 3rd quarter worth about $225,000. Hedge funds and other institutional investors own 77.94% of the company’s stock.

A number of analysts recently issued reports on ONCE shares. Royal Bank Of Canada reiterated a “buy” rating on shares of Spark Therapeutics in a research note on Wednesday, October 25th. Cantor Fitzgerald reiterated a “buy” rating on shares of Spark Therapeutics in a research note on Friday, August 25th. Raymond James Financial, Inc. started coverage on Spark Therapeutics in a research note on Thursday, October 12th. They set an “outperform” rating and a $96.00 price objective on the stock. Chardan Capital upgraded Spark Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $60.00 to $100.00 in a research note on Tuesday, August 8th. Finally, BidaskClub upgraded Spark Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, August 26th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and eighteen have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $90.36.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Insider Buying and Selling by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply